APPENDIX C – ROYALTIES. Royalties:
APPENDIX C – ROYALTIES. Royalties: The Licensee agrees to pay to the IC a noncreditable, nonrefundable license issue royalty in the amount of ________ dollars ($X) within sixty (60) days from the effective date of this Agreement. The Licensee agrees to pay to the IC a nonrefundable annual royalty in the amount of ________ dollars ($X) as follows: The first annual royalty is due within sixty (60) days of the effective date of this Agreement and may be prorated according to the fraction of the calendar year remaining between the effective date of this Agreement and the next subsequent January 1; and Subsequent annual royalty payments are due and payable on January 1 of each calendar year.
APPENDIX C – ROYALTIES. Royalties: The Licensee agrees to pay to the IC a noncreditable, nonrefundable license issue royalty in the amount of _______ Dollars ($X) within sixty (60) days from the effective date of this Agreement. The Licensee agrees to pay to the IC a nonrefundable minimum annual royalty in the amount of _______ Dollars ($X) as follows: The first minimum annual royalty is due within sixty (60) days of the effective date of this Agreement and may be prorated according to the fraction of the calendar year remaining between the effective date of this Agreement and the next subsequent January 1; and Subsequent minimum annual royalty payments are due and payable on January 1 of each calendar year and may be credited against any earned royalties due for sales made in that year. The Licensee agrees to pay the IC earned royalties of ___ percent (X%) on Net Sales by or on behalf of Licensee or its sublicensees. The Licensee agrees to pay the IC Benchmark royalties within sixty (60) days of achieving each Benchmark: The Licensee agrees to pay the IC additional sublicensing royalties of ____ percent (X%) on the fair market value of any consideration received for granting each sublicense within sixty (60) days of the execution of each sublicense.
APPENDIX C – ROYALTIES. Royalties: LICENSEE agrees to pay to PHS a noncreditable, nonrefundable license issue royalty in the amount of [CONFIDENTIAL TREATMENT REQUESTED]. LICENSEE agrees to pay to PHS a nonrefundable minimum annual royalty in the amount of [CONFIDENTIAL TREATMENT REQUESTED]. LICENSEE shall pay PHS earned royalties at the rate of [CONFIDENTIAL TREATMENT REQUESTED] % on NET SALES of up to [CONFIDENTIAL TREATMENT REQUESTED] per annum and [CONFIDENTIAL TREATMENT REQUESTED] % on said NET SALES over [CONFIDENTIAL TREATMENT REQUESTED] per annum of LICENSED PRODUCTS made, used, or sold by LICENSEE and/or its SUBLICENSEES. LICENSEE agrees to pay PHS benchmark royalties as follows: ONCOLOGY [CONFIDENTIAL TREATMENT REQUESTED] at the completion of Phase 1 phenylbutyrate studies. Expected completion date – early 1996. [CONFIDENTIAL TREATMENT REQUESTED] at the completion of Phase II studies for either phenylbutyrate or phenylacetate. Expected completion date – late 1997 to early 1998. [CONFIDENTIAL TREATMENT REQUESTED] at the completion of Phase III studies for either phenylacetate or phenylbutyrate (whichever compound is found to be more efficacious) and filing of NDA. Expected completion date – late 2000. [CONFIDENTIAL TREATMENT REQUESTED] upon approval for the commercial sale of a Licensed Product, by the FDA or foreign functional equivalent, this royalty to apply only in the first country approved, if that country is the United States, Japan, or the first country in Europe. [CONFIDENTIAL TREATMENT REQUESTED] upon approval for the commercial sale of a Licensed Product by the FDA or foreign functional equivalent in subsequent countries approved, this royalty to apply only in the United States, in Japan, and the first country in Europe.
APPENDIX C – ROYALTIES. [This appendix has been redacted in its entirety]
APPENDIX C – ROYALTIES. Royalties: The Licensee agrees to pay to the IC a noncreditable, nonrefundable license issue royalty in the amount of _______ Dollars ($X) within sixty (60) days from the effective date of this Agreement. The Licensee agrees to pay to the IC a nonrefundable minimum annual royalty in the amount of _______ Dollars ($X) as follows: The first minimum annual royalty is due within sixty (60) days of the effective date of this Agreement and may be prorated according to the fraction of the calendar year remaining between the effective date of this Agreement and the next subsequent January 1; and Subsequent minimum annual royalty payments are due and payable on January 1 of each calendar year and may be credited against any earned royalties due for sales made in that year. The Licensee agrees to pay the IC earned royalties of ___ percent (X%) on Net Sales by or on behalf of the Licensee. The Licensee agrees to pay the IC Benchmark royalties within sixty (60) days of achieving each Benchmark:
APPENDIX C – ROYALTIES. Royalties: Licensee agrees to pay to PHS a noncreditable, nonrefundable license issue royalty in the amount of [*] Dollars ($[*]). Licensee agrees to pay to PHS a nonrefundable minimum annual royalty in the amount of [*] Dollars ($[*]) beginning January 1, 1999. Licensee agrees to pay PHS earned royalties on Net Sales by or on behalf of Licensee as follows: [*] Percent ([*]%) of Net Sales of Licensed Products by Licensee or its sublicensees; and Licensee shall be entitled to a [*] Percent ([*]%) credit against the earned royalty rate on Net Sales for each [*]Percent ([*]%) of royalty Licensee must pay in excess of [*] Percent ([*]%) to unaffiliated third party licensors for the manufacture and sale of Licensed Products. However, in no instance shall the earned royalty rate for PHS be reduced below [*] Percent ([*]%). Licensee agrees to pay PHS benchmark royalties as follows: [*] Dollars ($[*]) upon initiation of the first Phase III Clinical Trial for Licensed Products; and [*] Dollars ($[*]) upon marketing approval in the United States for Licensed Products. Licensee agrees to pay PHS additional royalties for unreimbursed patent prosecution expenses as set forth in Paragraphs 6.08 and 6.09.
APPENDIX C – ROYALTIES. Royalties: The Licensee agrees to pay to the NIH a noncreditable, nonrefundable license issue royalty in the amount of ________ dollars ($X) within sixty (60) days from the effective date of this Agreement. The Licensee agrees to pay to the NIH a nonrefundable annual royalty in the amount of ________ dollars ($X) as follows: The first annual royalty is due within sixty (60) days of the effective date of this Agreement and may be prorated according to the fraction of the calendar year remaining between the effective date of this Agreement and the next subsequent January 1; and Subsequent annual royalty payments are due and payable on January 1 of each calendar year.
